#Japan #Tokyo #Lecanemab #Eisai #Leqembi

Eisai to Present Long-Term Data on Lecanemab at AD/PD 2026 Conference

Eisai Co., Ltd., headquartered in Tokyo and led by CEO Haruo Naito, recently announced its plans to present the latest data on lecanemab at the upcoming AD/PD™ 2026 Annual Meeting. This significant event will take place in Copenhagen, Denmark, from March 17-21, 2026, and will also be accessible online. Lecanemab, marketed as LEQEMBI® in the U.S., is an innovative treatment that targets amyloid beta (Aβ) protofibrils, contributing to the fight against Alzheimer's disease (AD).

Key Findings to be Presented

Eisai's findings will be highlighted through six presentations at the conference, which includes three oral reports. Among these, the company will discuss a U.S.-based long-term treatment persistence study that showcases the efficacy and safety outcomes of lecanemab, particularly in patients who are homozygous for the apolipoprotein E ε4 allele (ApoEε4). In addition, results from a four-year follow-up in the Clarity AD Open-Label Extension trial focusing on non-ApoEε4 carriers and heterozygotes will also be shared. Moreover, a genome-wide association study revealing novel genetic variants linked to cognitive decline in AD is set to be presented as well.

Promotional Symposium Highlights

In conjunction with its presentations, Eisai is set to sponsor a symposium titled “Continue Life Their Way: Early Intervention in Alzheimer’s Disease.” This event will feature four renowned experts in AD, discussing the imperative nature of early intervention and continuous treatment in improving patient outcomes. The symposium intends to reinforce the concept of AD as a chronic disease that necessitates a multidisciplinary approach to care. It aims to enhance medical professionals’ understanding of how real-world evidence can significantly contribute to patient assessment practices.

Oral Presentation Schedule

The following are the details of Eisai's oral presentations at the conference:

• - Lecanemab Real-World Outcomes and Mechanistic Insights in Anti-Amyloid Treatment

- Date: Friday, March 20
- Time: 16:50-17:05 CET
- Content: Safety and effectiveness data from a retrospective real-world study of E4/E4 homozygous patients.

• - Long-Term Persistence and Patient Characteristics for Lecanemab in Real-World Use in the U.S.

- Date: Friday, March 20
- Time: 17:05-17:20 CET

Poster Presentations Overview

Eisai will also present several posters relating to its ongoing studies, with titles including:

• - Lecanemab for Early Alzheimer's Disease: 48-month results from the Clarity AD Open Label Extension.
• - Reduction of Brain Aβ Protofibrils: Correlation with CSF pTau217 and neuronal biomarkers in APPNL-G-F/MAPT double-knock-in mice.
• - Development of a Fully Automated Plasma pTau205 Immunoassay: Demonstrating high correlation with an immunoprecipitation mass spectrometry assay in cooperation with Sysmex.

Conclusion

Eisai takes the lead in the development of lecanemab, collaborating closely with Biogen for its commercial rollout. The company is steadfast in its mission to provide groundbreaking treatments for Alzheimer’s, underlined by their ongoing clinical evaluations, regulatory approvals, and the impactful real-world data to be showcased at the AD/PD™ 2026 Meeting. As lecanemab continues to gain traction across various regions, including Japan, the United States, and Europe, the focus remains on enhancing patient care through innovative treatments and comprehensive understanding of Alzheimer’s disease.